Observational Registry of Basal Insulin Treatment ( ORBIT ) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real‐life use of basal insulin in China
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: To examine treatment patterns following basal insulin ( BI ) introduction in type 2 diabetes mellitus ( T2DM ) patients under real‐world conditions across C hina. Materials and methods: Overall, 18 995 patients inadequately controlled ( HbA1c ≥ 53 mmol/mol [7%]) with oral antihyperglycaemic drugs ( OADs ) and willing to receive BI treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2) and 6 months (visit 3). Type of BI was initiated at physicians’ discretion. Results: Retention with BI therapy at 6 months was 75.6%. Use of long‐acting BI predominated, with insulin glargine accounting for 71%, detemir 13% and Neutral Protamine Hagedorn ( NPH ) insulin 16%. Over 70% of long‐acting users maintained the same initial BI at visit 3, while 40% of NPH users switched treatment and 24.4% of participants initiated BI with prandial insulin. The initial mean (± SD ) dose of BI and total insulin was 0.18 ± 0.07 and 0.25 ± 0.19 IU /kg, respectively, with a mean increase of daily dose by 0.03 and 0.02 IU /kg after 6 months, respectively. Only 56.6% of insulin users reported dose titration at visit 3. Mean HbA1c was 81 mmol/mol (9.6%) at baseline and 57 mmol/mol (7.4%) at 6 months. The frequency of hypoglycaemia was 1.61 and 2.07 episodes/patient‐year at baseline and 6 months, respectively. Conclusions: In real‐world clinical settings, add‐on BI therapy in T2DM patients is associated with significant improvement in glycaemic control without overtly compromising safety related to hypoglycaemia and weight gain. Evolution of insulin treatment regimens varied among patients, but dose titration was suboptimal. More active BI dose titration might further improve glycaemic outcome in patients receiving BI therapy. Video Abstract: A free Video Abstract to accompany this article is available at https://vimeo.com/212655959
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
A Primer on Effectiveness and Efficacy Trials
Singal, A. G., Higgins, P. D. R., & Waljee, A. K. (2014) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2013.13 · Cited by 698
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008) · Diabetologia · doi:10.1007/s00125-007-0911-x · Cited by 447 · cited 1×
“addition of insulin glargine or insulin detemir to OADs and found effective glycaemic control and a low rate of hypoglycaemia with both BIs; however, insulin detemir was associated with more injection-site reactions and less weight gain compared with insulin glargine.(38) The initial dose of BI in the ORBIT study was…”
BackgroundStandards of care for type 2 diabetes in China
Weng, J., Ji, L., Jia, W., Lu, J., Zhou, Z., Zou, D., Zhu, D., Chen, L., Chen, L., Guo, L., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2827 · Cited by 315
Self-citationEsposito, K., Chiodini, P., Bellastella, G., Maiorino, M. I., & Giugliano, D. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01512.x · Cited by 136 · cited 1×
“is associated with a lower proportion of patients reaching target HbA1c levels during follow-up.(35,36) Therefore, the percentage of patients achieving the HbA1c target should also be considered when assessing the efficacy of insulin therapies.”
BackgroundThomsen, R. W., Baggesen, L. M., Søgaard, M., Pedersen, L., Nørrelund, H., Buhl, E. S., Haase, C. L., & Johnsen, S. P. (2015) · Diabetologia · doi:10.1007/s00125-015-3698-1 · Cited by 32
Cited by
Identification of barriers to insulin therapy and approaches to overcoming them
Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238
“In addition, modest titration of basal insulin in a real-world setting has been observed in studies from Germany,80 New Zealand81 and China.82 This is in contrast to data from the plethora of clinical trials74,75 that entail close monitoring by trial staff of motivated participants following strict titration algorithm…”
ResultInfluentialMorieri, M. L., Rigato, M., Frison, V., Simioni, N., D'Ambrosio, M., Tadiotto, F., Paccagnella, A., Lapolla, A., Avogaro, A., & Fadini, G. P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154190 · Cited by 31
Comparative effectiveness and safety of different basal insulins in a real-world setting
Ji, L., Zhang, P., Zhu, D., Lu, J., Guo, X., Wu, Y., Li, X., Ji, J., Jia, W., Yang, W., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12920 · Cited by 13
“A previous paper reported real-world BI treatment patterns, focusing on initiation and following the evolution of treatment regimens and insulin dosing, as well as the effect on overall blood glucose control and safety issues.(22) Based on the ORBIT study, this analysis aims to compare the safety and effectiveness of…”
MethodResultInfluentialSelf-citation
Metadata
- Authors
- Ji, L., Zhang, P., Zhu, D., Li, X., Ji, J., Lu, J., Guo, X., Jia, W., Weng, J., Wu, Y., Yang, W., Zou, D., Zhou, Z., Pan, C., Gao, Y., & Garg, S. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-17
- Volume
- 19
- Issue
- 6
- Pages
- 822-830
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2573858888
- Cited by
- 54
- References
- 8
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.